TrialHaematologica2022

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study.

Simon Rule et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.